Brief: Xilio Therapeutics Announces Preliminary Clinical Data From Phase 1 Trial Of Xtx101, A Tumor-Activated, FC-Enhanced Anti-Ctla-4, In Patients With Advanced Solid Tumors
25/05/2023 23:19
Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS ANNOUNCES PRELIMINARY CLINICAL DATA
FROM
PHASE 1 TRIAL OF XTX101, A TUMOR-ACTIVATED, FC-ENHANCED
ANTI-CTLA-4, IN PATIENTS WITH ADVANCED SOLID TUMORS
* FAVORABLE PRELIMINARY SAFETY PROFILE FOR XTX101 OBSERVED
AT
RECOMMENDED PHASE 2 DOSE OF 150 MG ONCE EVERY SIX WEEKS
* XILIO THERAPEUTICS- ENCOURAGING PRELIMINARY ANTI-TUMOR
ACTIVITY
OBSERVED IN A PATIENT WITH PD-L1 NEGATIVE ADVANCED NON-SMALL
CELL LUNG CANCER
Source text for Eikon: ID:nGNX4qqm4c
Further company coverage: XLO.O
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla